All Hong Kong stocks quotes are at least 15 minutes delayed.
02171
CARSGEN-B
HKD
13.890-0.240
(-1.70%)
1D
AI Analysis
High
14.350
Open
14.130
VWAP
13.72
Vol
1.75M
Mkt Cap
10.48B
Low
13.500
Amount
24.06M
EV/EBITDA(TTM)
--
Total Shares
574.07M
EV
865.05M
EV/OCF(TTM)
--
P/S(TTM)
84.79
CARsgen Therapeutics Holdings Ltd is an investment holding company primarily engaged in discovering, researching and developing cell therapies. The Company’s main business is engaged in developing chimeric antigen receptor T cell (CAR T) -cell therapies to address clinical needs including but not limited to hematologic malignancies solid tumors and autoimmune diseases. The Company’s main products include zevor-cel (zevorcabtagene autoleucel), satricabtagene autoleucel and allogeneic CAR T-cell products. The Company conducts its business in the domestic and overseas markets.
Show More
Money Flow
Over the past 66 trading days, overall net money flow is -960.00K, with retail investors contributing 1.49M and major investors adding 2.28M.
Net Buy $ Volume
Net Sell $ Volume
No data
Valuation Metrics
Forward PE
N/A
5Y Average PE
-12.61
Current PE
-41.98
Overvalued PE
1.12
Undervalued PE
-26.35
Forward EV/EBITDA
N/A
5Y Average EV/EBITDA
-10.42
Current EV/EBITDA
-29.90
Overvalued EV/EBITDA
1.10
Undervalued EV/EBITDA
-21.94
Forward PS
N/A
5Y Average PS
43.41
Current PS
7.53
Overvalued PS
124.72
Undervalued PS
-37.90
Financials
AI Analysis
Annual
Quarterly
Trading Trends
Daily
Monthly
Buyback
Short Selling
People Also Watch